Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Coding Corner Question

Staff  |  Issue: January 2009  |  January 1, 2009

Billing for Rheumatoid Arthritis with an Adverse Reaction to Infliximab

A 60-year-old female with severe rheumatoid arthritis presented for her third dose of infliximab. The patient is also currently on methotrexate and prednisone. The physician questioned the patient to make sure there was no active infection and recommended that the patient begin the infliximab infusion. The patient had no additional questions, and an extended counseling session to review the risks and benefits of infliximab did not need to be repeated, because this had been done during the last visit.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Thirty-five minutes into the infusion (200 mg of infliximab), the patient started to have an adverse reaction to the infliximab. The patient’s IV line was flushed with saline, and diphenhydramine was pushed into the IV to counter the allergic reaction. The infusion was discontinued.

There was a problem-focused history and a detailed examination done. The medical decision making was of moderate complexity. The patient was scheduled for a follow-up visit in a week.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

How would you code this?

Click here for the answer.

Share: 

Filed under:Billing/CodingPractice Support Tagged with:BillingCodinginfliximabRheumatoid arthritis

Related Articles

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    August 16, 2019

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    Reading Rheum

    July 1, 2007

    Handpicked Reviews of Contemporary Literature

    Practice Page: Is In-house or Outsourced Medical Billing Right for Your Physician Practice?

    February 1, 2014

    What to consider when deciding whether to delegate claims billing in-house or to contract with an outside company

    MicroOne / shutterstock.com

    Rheumatology Drugs at a Glance, Part 2: Psoriasis

    May 17, 2019

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences